DSGN Q3 2024 Earnings — Design Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DSGNDesign Therapeutics, Inc.

$569M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$16M

Net Income

-$13M

EPS (Diluted)

$-0.23

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$262M

Total Liabilities

$9M

Stockholders' Equity

$252M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$137,000	+100.0%
Operating Income	-$16M	-$19M	+13.7%
Net Income	-$13M	-$16M	+17.4%